TL;DR
Get everyday helpers delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Cochlear has completed recruitment for two pivotal studies of its investigational fully implantable cochlear implant system. The company says participants across its research program have accumulated more than 1 million hours of experience with devices that remain unapproved for commercial use.
Cochlear says it has completed recruitment for two worldwide pivotal studies of its investigational fully implantable cochlear implant system, with participants in its broader research program accumulating more than 1 million hours of device experience. The milestone marks progress toward evaluating the system’s safety and performance, but the technology is not approved for commercial distribution.
The pivotal program includes ELEVATE, conducted at 11 sites in the United States, and ENTERPRISE, conducted at five sites in Europe and Australia. Together, the studies enrolled 92 adults: ELEVATE was designed for 56 participants and ENTERPRISE for 36. The company says recruitment is complete, while follow-up and data collection continue.
Across the full research effort, including three earlier feasibility studies that began in 2005, Cochlear reports that 117 people have enrolled and that participants have used three generations of investigational devices. The company says the program has accumulated more than one million hours of patient experience. It has not provided a breakdown of those hours by study, device generation, or individual participant in the supplied report.
The studies plan a primary safety and effectiveness analysis at six months, with participant follow-up continuing to 12 months. Cochlear says it is advancing development toward regulatory submissions. The announcement does not state when those submissions will be made or when regulators might reach a decision.
Evidence Before Wider Use
Completing recruitment allows the pivotal studies to focus on follow-up and analysis, steps needed to assess how the system performs and what risks may arise. The six-month primary analysis and continued observation through 12 months are intended to contribute clinical data for the investigational technology. The reported million hours describes accumulated participant experience; by itself, it does not establish safety, effectiveness, or benefit.
A fully implantable system could change how recipients use cochlear implant technology during daily activities, because the device is intended to be implanted rather than relying on externally worn components. Cochlear lists all-day hearing performance, battery longevity, internal microphones, surgical simplicity, and long-term clinical evidence among its development priorities. Whether the system meets those goals remains to be shown by study results and regulatory review.
For people who may benefit from cochlear implants now, the announcement does not change current treatment options. ELEVATE coordinating investigator Craig Buchman said eligible people should not wait for future fully implantable devices, describing current cochlear implant technology as proven and available to provide access to sound and potential communication and quality-of-life benefits.
From Feasibility to Pivotal Trials
Cochlear says its research program spans three generations of investigational devices and more than 20 years, beginning with feasibility work in 2005. The current announcement concerns the transition to large pivotal studies, rather than a commercial launch or a regulatory clearance.
The company identified four priorities informed by its research to date: reliable hearing throughout the day and sufficient battery life; internal dual microphones designed to address body noise; a familiar surgical approach intended to limit added operating-room and anesthesia time; and confidence supported by long-term clinical data and recipient input. These are development priorities described by Cochlear, not results established by the announcement.
The investigational system has not been approved for commercial distribution, and its safety and effectiveness have not been established. The company’s latest commercially available cochlear implant named in the report is the Cochlear Nucleus Nexa System. Regulatory evaluation would be required before the fully implantable system could be sold.
“We now have more than 20 years of experience across three generations of investigational devices.”
— Dig Howitt, Cochlear CEO and president
Results and Approval Remain Pending
The announcement reports recruitment and cumulative device-use hours, but it does not provide study outcomes on safety, hearing performance, adverse events, or recipient-reported quality of life. Those questions await the planned analyses and ongoing follow-up. The report also gives no date for completion of the 12-month follow-up or publication of the findings.
It remains unclear when Cochlear will submit data to regulators, which regulatory milestones would follow, or whether the system will ultimately be authorized for sale. The million-hour figure is a measure of accumulated experience across the research program, not a regulatory finding or proof of benefit.
Follow-Up and Regulatory Submissions
Participants in ELEVATE and ENTERPRISE are expected to continue follow-up through 12 months, while researchers collect data for the planned six-month primary analysis of safety and effectiveness. Cochlear says it will use the ongoing work to advance development toward regulatory submissions.
Readers can expect further updates when the company or investigators report study findings or regulatory steps. Until the results are available and regulators complete their review, the system remains investigational and unavailable for commercial distribution.
Key Questions
What did Cochlear announce?
Cochlear announced that recruitment is complete for its ELEVATE and ENTERPRISE pivotal studies of an investigational fully implantable cochlear implant system. It also reported more than 1 million hours of participant experience across its broader research program.
How many people enrolled in the pivotal studies?
The two studies enrolled 92 adults combined: 56 in ELEVATE and 36 in ENTERPRISE, according to the report.
Is the fully implantable system available to patients?
No. The report says the system is not approved for commercial distribution, and its safety and effectiveness have not yet been established.
What happens after recruitment?
Follow-up and data collection continue. A primary analysis of safety and effectiveness is planned at six months, with follow-up through 12 months; Cochlear says it is advancing development toward regulatory submissions.
Should patients wait for this technology before considering a cochlear implant?
Study investigator Craig Buchman said people who could benefit from a cochlear implant today should not wait for future fully implantable devices. Treatment decisions should be discussed with a qualified hearing care professional.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
